PRESS RELEASE | MULHOUSE, FRANCE - May 20, 2025

CellProthera Selects CELL*for*CURE by SEQENS for Phase 3 GMP Manufacturing

First clinical batches of ProtheraCytes® planned for 2026

CellProthera, a regenerative cell therapy developer specializing in ischemic diseases, has chosen CELL*for*CURE by SEQENS, as its contract development and manufacturing organization (CDMO) partner for its planned Phase 3 trial for ProtheraCytes®, its autologous expanded CD34+ stem cell-based therapy aimed at improving heart failure event-free survival following a severe heart attack. CellProthera will tech transfer to CELL*for*CURE by SEQENS this year, with plans to produce clinical batches starting in 2026.

With promising results from a Phase 1/2b study of its lead ProtheraCytes®, CellProthera has begun preparations for its late stage of clinical development. Last year, the company presented its Phase 3 design to FDA and received favorable advice. Tech transfer and qualification of the bioproduction process in a specialized facility capable of releasing clinical batches of cellular products is an essential prerequisite for the start of Phase 3.

"Having a partner with expertise in advanced stage of clinical development and commercialization of cell and gene therapies adds substantial value for CellProthera as we enter the final phase of development for ProtheraCytes, looking at Phase 3 and through to market authorization," said Matthieu De Kalbermatten, CEO of CellProthera.

"We selected CELL*for*CURE by SEQENS for the quality of its infrastructure, its equipment and the expertise of its team, who has already demonstrated its ability to release commercial batches of autologous therapies," said Jean-Olivier Hirsch, Chief Operating Officer and Qualified Person of CellProthera.

"We look forward to supporting CellProthera at this critical juncture for ProtheraCytes' development," said Marc-Olivier Mignon, President of CELLforCURE by SEQENS. "Our ability to embrace innovative technologies and scale up production for late-stage clinical trials will help accelerate the investigation of potential new therapies."

About CellProthera

CellProthera is a regenerative cell therapy developer specializing in ischemic diseases, with a leading program in myocardial infarction. CellProthera has developed a unique GMP-compliant cell expansion process as well as a proprietary automation technology for in vitro production of a large quantity of purified, expanded CD34+ stem cells. Its lead therapy ProtheraCytes®, is an autologous cell therapy targeted to regenerate various damaged tissues, including cardiac tissue. ProtheraCytes is registered as an Advanced Therapy Medicinal Product – ATMP – by the European Medicines Agency (EMA). CellProthera's proprietary technology platform comprises an automated expansion device called StemXpand® and its single use kit StemPack®. CellProthera is headquartered in Mulhouse, France.

About CELL*for*CURE by SEQENS

CELL*for*CURE by SEQENS is a CDMO authorized by ANSM, dedicated to ATMPs production from concept to commercialization. With advanced technologies, extensive capabilities, and large-scale capacity, CELL*for*CURE by SEQENS offers a seamless journey from early-stage development to commercial manufacturing of a wide range of cell therapies.
SEQENS Group is a global partner in health, personal care and specialty ingredients, leveraging 3300 employees, 16 manufacturing sites and 9 R&D centers in 9 countries.

press@seqens.com / cellandgene.seqens.com / LinkedIn : CELL*for*CURE by SEQENS